Location of Repository

Strengths and Weaknesses of Immunotherapy for Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of 12 Randomized Controlled Trials

By Juan Wang, Ze-Hong Zou, Hong-Lin Xia, Jian-Xing He, Nan-Shan Zhong and Ai-Lin Tao
Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:3293858
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Preview

    Citations

    1. (1994). A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small-cell lung cancer.
    2. (2009). Active specific immunotherapy and celltransfer therapy for the treatment of non-small-cell lung cancer.
    3. (2010). Adverse events among the elderly receiving chemotherapy for advanced nonsmall-cell lung cancer.
    4. (2004). Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer.
    5. (2011). Antiangiogenic agents for the treatment of nonsmall-cell lung cancer: characterizing the molecular basis for serious adverse events.
    6. (1999). Assessing the quality of randomized trials: reliability of the Jadad scale.
    7. (1996). Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
    8. (2010). Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.
    9. (2009). Cetuximab plus chemotherapy in patients with advanced non-small-cell lung
    10. (2011). Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review.
    11. (2011). Global cancer statistics.
    12. (2011). Immunotherapy as a strategy for the treatment of non-small-cell lung cancer.
    13. Localio A (2007) Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events.
    14. (2009). Lung cancer-associated tumor antigens and the present status of immunotherapy against non-small-cell lung cancer.
    15. (2010). Maintenance and consolidation therapy in patients with unresectable stage III/IV non-small-cell lung cancer.
    16. (2001). Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer.
    17. (2008). Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer.
    18. (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
    19. (2002). Quantifying heterogeneity in a meta-analysis.
    20. (2008). Randomized phase II clinical trial of chemoimmunotherapy in advanced non-small-cell lung cancer.
    21. (2004). Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.
    22. (2005). Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer.
    23. (1972). Regression models and life-tables.
    24. (2004). SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced nonsmall-cell lung cancer: phase III results.
    25. (2011). The optimal chemotherapy for stage III non-small cell lung cancer patients.
    26. (2010). Vaccines and immunotherapy for non-small-cell lung cancer.
    27. (2009). Vaccines for the treatment of non-small-cell lung cancer: a renewed anticancer strategy.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.